Medical Therapies buys midkine IP
Thursday, 03 July, 2008
Sydney pharma Medical Therapies [ASX: MTY] has completed the purchase of the IP surrounding midkine protein-related technology assets from Japanese company Cell Signals Inc after receiving shareholder approval.
Cell Signals today traded all midkine protein-related IP rights to Medical Therapies, in exchange for 20 million shares of Medical Therapies stock.
These include patents, trademarks, manufacturing information and technical know-how, on top of all Cell Signals' stocks of midkine protein and reagents.
The agreement was announced in April. Midkine is a neurite growth promoting factor, active in oncogenesis and inflammation.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
